Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two ...Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on residual old bone. An increase in bone formation and a subsequent decrease were observed in the preliminary simulation. For each fitted time point, the predicted value was compared to the absolute values of the bone formation and resorption markers and lumbar BMD. The simulation model strongly matched actual changes in bone turnover markers and BMD. This simulation model indicates increased bone formation marker levels in the early stage and a subsequent decrease. It is therefore concluded that remodeling-based bone formation persisted during the entire treatment period with once-weekly teriparatide.展开更多
Osteoporosis is a typical physiological disease,the main symptoms of which are brittle fracture,bone pain and easily deformed.As an individual ages,the prevalence of osteoporosis increases year by year.In the present ...Osteoporosis is a typical physiological disease,the main symptoms of which are brittle fracture,bone pain and easily deformed.As an individual ages,the prevalence of osteoporosis increases year by year.In the present study,selenium with antioxidant,immunomodulatory and anti-tumor effects was used to prevent osteoporosis induced by retinoic acid.The serum calcium contents in the selenium-treated groups(sodium selenite and selenomethionine)were significantly higher(P<0.05)than those in the model group in both the prevention and treatment studies.After pre-vention,glutamic-oxalacetic transaminase transaminase(GOT),glutamate transaminase(GPT),alkaline phosphatase(ALP)and tartrate-resistant acid phosphatase(TRACP)levels were significantly(P<0.05)decreased.In the treatment study,the serum calcium and phosphorus contents of the rats increased after selenium treatment.There was no significant change(P>0.05)in the activity of GOT and GPT.The content of ALP decreased obviously and the TRACP enzyme activity increased.Overall,these results showed that different forms of selenium compounds have great potential in preventing and treating osteoporosis.展开更多
文摘Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on residual old bone. An increase in bone formation and a subsequent decrease were observed in the preliminary simulation. For each fitted time point, the predicted value was compared to the absolute values of the bone formation and resorption markers and lumbar BMD. The simulation model strongly matched actual changes in bone turnover markers and BMD. This simulation model indicates increased bone formation marker levels in the early stage and a subsequent decrease. It is therefore concluded that remodeling-based bone formation persisted during the entire treatment period with once-weekly teriparatide.
文摘Osteoporosis is a typical physiological disease,the main symptoms of which are brittle fracture,bone pain and easily deformed.As an individual ages,the prevalence of osteoporosis increases year by year.In the present study,selenium with antioxidant,immunomodulatory and anti-tumor effects was used to prevent osteoporosis induced by retinoic acid.The serum calcium contents in the selenium-treated groups(sodium selenite and selenomethionine)were significantly higher(P<0.05)than those in the model group in both the prevention and treatment studies.After pre-vention,glutamic-oxalacetic transaminase transaminase(GOT),glutamate transaminase(GPT),alkaline phosphatase(ALP)and tartrate-resistant acid phosphatase(TRACP)levels were significantly(P<0.05)decreased.In the treatment study,the serum calcium and phosphorus contents of the rats increased after selenium treatment.There was no significant change(P>0.05)in the activity of GOT and GPT.The content of ALP decreased obviously and the TRACP enzyme activity increased.Overall,these results showed that different forms of selenium compounds have great potential in preventing and treating osteoporosis.
